Description: Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Home Page: www.quantumbiopharma.com
55 University Ave.
Toronto,
ON
M5J 2H7
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Zeeshan Saeed | Founder, CEO, President & Executive Co-Chairman |
| Mr. Anthony John Durkacz | Founder & Executive Co-Chairman |
| Mr. Donal Carroll CPA | CFO & COO |
| Mr. Nathan Coyle CPA | Controller |
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | CEO of Lucid & Director |
| Mr. Jason D. Sawyer | Head of Finance & Mergers and Acquisitions |
| Ms. Maryann Adesso | Corporate Secretary |
| Randell Mack | President of FSD BioSciences |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical & Scientific Affairs of Lucid |
| Mr. Kevin Cassidy | Vice President of Quality-Lucid |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5527 |
| Price-to-Sales TTM: | 91.8563 |
| IPO Date: | 2018-06-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |